Fiotec was invited to participate in the General Assembly Meeting of the Ending Covid-19 Variants of Concern Through Cohort Studies project, in Barcelona. The consortium is funded by the European Commission and involves partners from several countries that support the European and global response to the Covid-19 pandemic and variants of concern, in order to support control strategies and diagnostic development; assess the impact of variants on the effectiveness of different vaccines and vaccination strategies; investigate how variants alter long-term post-infection sequelae; and assess the implications of variants in choosing optimal treatment options.
The event took place at the Instituto de Salud Global Barcelona (ISGlobal), from June 6th and 8th, where all researchers were able to present the evolution of the study in their respective spheres. On the first day, the general presentation took place, and the other two were dedicated for individual meetings and presentation of the WPs and their evolutions.
The researcher André Siqueira (member of the Executive Board), Maria Paula Mourão (Joint PI of the study) and Evelyn Santos, coordination assistant, attended the event as Fiocruz representatives. Erica Nascimento and Sara Junker, responsible for managing the project, were representing Fiotec.
Sara Junker said that it was an opportunity to integrate with the coordination: “Since they are from Amazonas, we only met virtually, so this contact makes a lot of difference to bring the relationship closer. We were also able to understand more about the role of Fiotec, which manages the administrative part so that the researcher can be fully dedicated to the research.”
Get to know the ultimate goal of the project
The primary objective of the study is to assess the effectiveness of vaccines in variants of Covid-19 through data from population cohort studies and samples from different locations where the consortium operates, to carry out epidemiological, observational, nested studies and laboratory investigations to establish the effectiveness of different vaccines and immunity against SARS-COV-2 VOC/VOIs.
